"Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19," he said. Coronavirus Pandemic More FDA authorizes over-the-counter combined COVID-19 and flu test ...
参考资料: [1]https://www.dailymail.co.uk/health/article-11624959/FDA-CDC-vaccine-advisers-angry-early-data-Covid-19-booster-shot-withheld-year.html [2]Chalkias S, Eder F, Essink B,et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against ...
The US drug company Moderna has announced that it is developing two new approaches to emerging variants of covid-19 after studies showed that its vaccine had a reduced level of neutralising titres to the South African variant, suggesting that immunity might wane. Although the studies showed that...
WASHINGTON, Dec. 20 (Xinhua) -- American biotechnology company Moderna announced Monday that preliminary data suggests its COVID-19 booster shot appears to increase antibody levels against the Omicron coronavirus variant. The currently authorized 50-microgram booster of Moderna's COVID-19 vaccine mRNA...
The Food and Drug Administration on Wednesday gave the companies the go-ahead to roll out their “bivalent” shots, which target both the original strain of Covid and the fast-spreading BA.4 and BA.5 subvariants, ahead...
Moderna is gearing up to halve the dose of its COVID-19 vaccine, the US drugmaker said on Wednesday, so that it can also be used to combat variants and inoculate children. It has agreed a deal with Swiss-based drugmaker Lonza which said a new drug substance production line in Geleen,...
Aug 23, 2022Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222 Jul 11, 2022Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutral...
The agency approved the use of a single booster dose of the Moderna COVID-19 vaccine at least 6 months after completion of the primary shots to people 65 years of age and older, 18 through 64 years of age at high risk of severe COVID-19, and 18 through 64 years of age with frequen...
(Xinhua) -- American biotechnology company Moderna submitted a request to the U.S. Food and Drug Administration (FDA) on Thursday for emergency use authorization (EUA) on a fourth dose of its COVID-19 vaccine for adults 18 years of age and older, who already received a booster dose of ...
Thus, additional booster doses may be needed to ensure individuals remain adequately protected, said the company. The FDA is set to convene its advisory committee of vaccine experts in April to deliberate how to arrange COVID-19 booster shots, including whether and when those boosters may be ne...